Study Description
The purpose of this study is to evaluate the safety, tolerability, dosimetry and
preliminary efficacy of [177Lu]Lu-EVS459 and the safety and imaging properties of
[68Ga]Ga-EVS459 in patients aged ≥ 18 years with advanced high-grade serous ovarian
cancer (OC) or locally advanced unresectable or metastatic non-squamous non-small cell
lung carcinoma (non-sq. NSCLC). The study will be done in two parts. The first part is called "escalation" and the second
part is called "expansion". In both parts of the study, patients will initially be imaged
with a [68Ga]Ga EVS459 positron emission tomography (PET)/computed tomography (CT) or
PET/magnetic resonance imaging (MRI) scan. In the escalation part, different doses of
[177Lu]Lu-EVS459 will then be tested to identify recommended dose(s) (RD(s)) for further
evaluation. The expansion part of the study will examine the safety and preliminary
efficacy of [177Lu]Lu-EVS459 at the RD(s) determined during the escalation part. The end
of study will occur when at least 80% of the patients in the expansion part have
completed the follow-up for disease progression or discontinued from the study for any
reason, and all patients have completed treatment and the 36-month long-term follow-up
period.
Interventions
[177Lu]Lu-EVS459
[68Ga]Ga-EVS459
Eligibility Criteria
Key Inclusion Criteria:
- Age >= 18 years old
- Patients with advanced high-grade serous ovarian cancer (OC) or locally advanced
unresectable or metastatic non-squamous non-small cell lung cancer (non sq. NSCLC)
with disease progression following, or intolerance to, at least 1 line of therapy
Key Exclusion Criteria:
- Absolute neutrophil count (ANC) < 1.5 x 10^9/L, hemoglobin < 10 g/dL, or platelet
count < 100 x 10^9/L
- QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
- Creatinine clearance < 60 mL/min
- Unmanageable urinary tract obstruction or urinary incontinence
- Radiation therapy within 4 weeks prior to the first dose of [177Lu]Lu-EVS459
Other protocol-defined inclusion/exclusion criteria may apply.
Novartis Investigative Site
Recruiting
Tel Aviv,6423906,Israel
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.